RBC Capital Reiterates Outperform on Viridian Therapeutics, Maintains $44 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has reiterated its Outperform rating on Viridian Therapeutics, maintaining a price target of $44.
September 19, 2024 | 2:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating on Viridian Therapeutics, maintaining a price target of $44. This suggests confidence in the company's future performance.
The reiteration of an Outperform rating and maintenance of a $44 price target by RBC Capital indicates a positive outlook on Viridian Therapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100